O

Orion Oyj
OMXH:ORNBV

Watchlist Manager
Orion Oyj
OMXH:ORNBV
Watchlist
Price: 45.23 EUR 1.89% Market Closed
Market Cap: 6.3B EUR
Have any thoughts about
Orion Oyj?
Write Note

Intrinsic Value

The intrinsic value of one ORNBV stock under the Base Case scenario is 60.97 EUR. Compared to the current market price of 45.23 EUR, Orion Oyj is Undervalued by 26%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ORNBV Intrinsic Value
60.97 EUR
Undervaluation 26%
Intrinsic Value
Price
O
Worst Case
Base Case
Best Case

Valuation Backtest
Orion Oyj

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ORNBV cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ORNBV?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Orion Oyj

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Orion Oyj

Provide an overview of the primary business activities
of Orion Oyj.

What unique competitive advantages
does Orion Oyj hold over its rivals?

What risks and challenges
does Orion Oyj face in the near future?

Summarize the latest earnings call
of Orion Oyj.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Orion Oyj.

Provide P/S
for Orion Oyj.

Provide P/E
for Orion Oyj.

Provide P/OCF
for Orion Oyj.

Provide P/FCFE
for Orion Oyj.

Provide P/B
for Orion Oyj.

Provide EV/S
for Orion Oyj.

Provide EV/GP
for Orion Oyj.

Provide EV/EBITDA
for Orion Oyj.

Provide EV/EBIT
for Orion Oyj.

Provide EV/OCF
for Orion Oyj.

Provide EV/FCFF
for Orion Oyj.

Provide EV/IC
for Orion Oyj.

Show me price targets
for Orion Oyj made by professional analysts.

What are the Revenue projections
for Orion Oyj?

How accurate were the past Revenue estimates
for Orion Oyj?

What are the Net Income projections
for Orion Oyj?

How accurate were the past Net Income estimates
for Orion Oyj?

What are the EPS projections
for Orion Oyj?

How accurate were the past EPS estimates
for Orion Oyj?

What are the EBIT projections
for Orion Oyj?

How accurate were the past EBIT estimates
for Orion Oyj?

Compare the revenue forecasts
for Orion Oyj with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Orion Oyj and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Orion Oyj against its competitors.

Analyze the profit margins
(gross, operating, and net) of Orion Oyj compared to its peers.

Compare the P/E ratios
of Orion Oyj against its peers.

Discuss the investment returns and shareholder value creation
comparing Orion Oyj with its peers.

Analyze the financial leverage
of Orion Oyj compared to its main competitors.

Show all profitability ratios
for Orion Oyj.

Provide ROE
for Orion Oyj.

Provide ROA
for Orion Oyj.

Provide ROIC
for Orion Oyj.

Provide ROCE
for Orion Oyj.

Provide Gross Margin
for Orion Oyj.

Provide Operating Margin
for Orion Oyj.

Provide Net Margin
for Orion Oyj.

Provide FCF Margin
for Orion Oyj.

Show all solvency ratios
for Orion Oyj.

Provide D/E Ratio
for Orion Oyj.

Provide D/A Ratio
for Orion Oyj.

Provide Interest Coverage Ratio
for Orion Oyj.

Provide Altman Z-Score Ratio
for Orion Oyj.

Provide Quick Ratio
for Orion Oyj.

Provide Current Ratio
for Orion Oyj.

Provide Cash Ratio
for Orion Oyj.

What is the historical Revenue growth
over the last 5 years for Orion Oyj?

What is the historical Net Income growth
over the last 5 years for Orion Oyj?

What is the current Free Cash Flow
of Orion Oyj?

Discuss the annual earnings per share (EPS)
trend over the past five years for Orion Oyj.

Business Breakdown

Orion Oyj, a Finnish pharmaceutical and diagnostics company, has a storied history that dates back to 1917, when it was formed to meet the healthcare needs of the Finnish population. Over the decades, Orion has evolved into a key player in the European healthcare landscape, driven by its commitment to innovation and high-quality products. The company operates in two main segments: Prescription Pharmaceuticals, which includes medication for various therapeutic areas such as pain management, oncology, and neurology; and Animal Health, offering veterinary medicines and healthcare solutions. With a robust pipeline of new drugs and a focus on research and development, Orion is well-positioned to...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Orion Oyj

Current Assets 834.8m
Cash & Short-Term Investments 152.5m
Receivables 297.6m
Other Current Assets 384.7m
Non-Current Assets 622.5m
Long-Term Investments 300k
PP&E 405.1m
Intangibles 204.1m
Other Non-Current Assets 13m
Current Liabilities 349.4m
Accounts Payable 74.8m
Other Current Liabilities 274.6m
Non-Current Liabilities 345.9m
Long-Term Debt 234.1m
Other Non-Current Liabilities 111.8m
Efficiency

Earnings Waterfall
Orion Oyj

Revenue
1.3B EUR
Cost of Revenue
-551.1m EUR
Gross Profit
707.9m EUR
Operating Expenses
-413.2m EUR
Operating Income
294.7m EUR
Other Expenses
-62.3m EUR
Net Income
232.4m EUR

Free Cash Flow Analysis
Orion Oyj

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Orion's Q1 showed strong performance with sales growing by 11% to EUR 308.5 million and operating profit increasing to EUR 56 million, a 1% uptick. Key contributors were better-than-expected Nubeqa royalties and Easyhaler sales. The company received a EUR 30 million milestone from Bayer and saw a substantial improvement in cash flow partly due to a EUR 41 million pension fund transfer. Orion reaffirms its financial goals, aiming for revenue growth beyond 8% CAGR and maintaining high equity and return ratios. CEO Liisa Hurme noted the positive impact of green initiatives on Easyhaler sales in the UK and Germany.

What is Earnings Call?
Fundamental Scores

ORNBV Profitability Score
Profitability Due Diligence

Orion Oyj's profitability score is 68/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Positive 3-Year Average ROIC
Positive Free Cash Flow
68/100
Profitability
Score

Orion Oyj's profitability score is 68/100. The higher the profitability score, the more profitable the company is.

ORNBV Solvency Score
Solvency Due Diligence

Orion Oyj's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Short-Term Solvency
Long-Term Solvency
70/100
Solvency
Score

Orion Oyj's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ORNBV Price Targets Summary
Orion Oyj

Wall Street analysts forecast ORNBV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ORNBV is 50.27 EUR with a low forecast of 35.35 EUR and a high forecast of 66.15 EUR.

Lowest
Price Target
35.35 EUR
22% Downside
Average
Price Target
50.27 EUR
11% Upside
Highest
Price Target
66.15 EUR
46% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ORNBV?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for ORNBV is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Orion Oyj

Country

Finland

Industry

Pharmaceuticals

Market Cap

6.4B EUR

Dividend Yield

3.58%

Description

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is headquartered in Espoo, Etela-Suomen and currently employs 3,355 full-time employees. The company went IPO on 2006-07-03. The firm is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.

Contact

ETELA-SUOMEN
Espoo
Orionintie 1A
+358104261.0
www.orion.fi

IPO

2006-07-03

Employees

3 355

Officers

President, CEO & Chairman of Executive Management Board
Dr. Liisa Hurme
Chief Financial Officer & Member of Group Executive Management Board
Mr. Rene Lindell M.Sc., Ph.D.
Senior VP of Corporate Functions, General Counsel, Secretary & Member of Executive Management Board
Mr. Olli Huotari Ll.M.
Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. Board
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)
Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. Board
Prof. Outi Vaarala M.D., Ph.D.
Senior VP of Global Operations & Member of Executive Management Board
Mr. Juhani Kankaanpaa
Show More
Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. Board
Mr. Niclas Lindstedt EMBA, M.Sc.
Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. Board
Mr. Hao Pan M.Sc.
Senior Vice President of People & Culture and Member of Management Board
Ms. Julia Irene Macharey
Investor Relations & Financial Communications Officer
Mr. Tuukka Hirvonen M.Sc.(Soc.)
Show Less

See Also

Discover More
What is the Intrinsic Value of one ORNBV stock?

The intrinsic value of one ORNBV stock under the Base Case scenario is 60.97 EUR.

Is ORNBV stock undervalued or overvalued?

Compared to the current market price of 45.23 EUR, Orion Oyj is Undervalued by 26%.

Back to Top